Receptor-interacting protein (RIP) and Sirtuin-3 (SIRT3) are on opposite sides of anoikis and tumorigenesis

Pachiyappan Kamarajan1, Turki Y Alhazzazi, Theodora Danciu

  • 1Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, Michigan 48109-1078, USA.

Cancer
|June 8, 2012
PubMed
Abstract

Insights

Receptor-interacting protein (RIP) negatively regulates sirtuin-3 (SIRT3) in oral cancer anoikis resistance. High SIRT3 and low RIP expression in anoikis-resistant cells promote aggressive oral squamous cell carcinoma (OSCC) development.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • Cross-talk between anoikis (cell death upon detachment) and survival pathways is critical for tissue homeostasis and cancer progression.
  • Receptor-interacting protein (RIP) kinase mediates Fas-induced cell death and integrin/FAK-mediated survival pathways.
  • Sirtuin-3 (SIRT3), a deacetylase, influences cell survival, metabolism, and tumorigenesis, suggesting potential roles in cancer signaling cross-talk.

Purpose of the Study:

  • To investigate the hypothesized cross-talk between SIRT3 and the Fas/RIP/integrin/FAK signaling network in oral squamous cell carcinoma (OSCC).
  • To elucidate the roles of RIP and SIRT3 in anoikis resistance and tumorigenesis of OSCC.

Main Methods:

  • Immunohistochemical staining and immunoblotting were used to analyze RIP and SIRT3 expression.
  • Overexpression and suppression techniques were applied in vitro and in vivo.
  • Human tissue microarrays of OSCC were examined.

Main Results:

  • RIP and SIRT3 exhibited inverse expression patterns in OSCC cells and tissues.
  • Suppression of RIP increased SIRT3 levels, while SIRT3 suppression did not affect RIP levels.
  • Anoikis-resistant OSCC cells (oraspheres) showed increased SIRT3 and decreased RIP expression, correlating with enhanced tumor burden and incidence in mice.
  • SIRT3 suppression reduced anoikis resistance and tumor incidence.

Conclusions:

  • RIP acts as an upstream negative regulator of SIRT3 in the context of anoikis resistance in OSCC.
  • An anoikis-resistant phenotype characterized by high SIRT3 and low RIP expression is associated with a more aggressive OSCC phenotype and contributes to tumorigenesis.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...